10-Q: Clearside Biomedical Reports Positive Topline Results from ODYSSEY Trial and Provides Third Quarter 2024 Financial Update

Clearside Biomedical announced positive topline results from its Phase 2b ODYSSEY trial for CLS-AX in wet AMD and provided a financial update for the third quarter of 2024, highlighting ongoing research and development efforts and financial challenges.

Summary

• Clearside Biomedical reported a net loss of $7.7 million for the three months ended September 30, 2024, and a net loss of $27.0 million for the nine months ended September 30, 2024.
• The company's cash, cash equivalents, and short-term investments totaled $23.6 million as of September 30, 2024.
• The company expects its current funds to support operations into the third quarter of 2025.
• Clearside is developing CLS-AX for wet AMD, with positive topline results from the ODYSSEY trial showing stable visual acuity and reduced injection frequency.
• The company is also exploring small molecules for geographic atrophy (GA) treatment.
• Clearside has strategic partnerships with companies like Bausch + Lomb, Arctic Vision, and BioCryst Pharmaceuticals.
• The company's first commercial product, XIPERE, is licensed to Bausch + Lomb in the US and Canada and Arctic Vision in the Asia Pacific region.
• The company has received ISO and EC certifications for its SCS Microinjector.
• Clearside has an accumulated deficit of $348.0 million as of September 30, 2024.
• The company anticipates continuing to incur significant operating losses for the next several years.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. The positive topline results from the ODYSSEY trial are encouraging, but the company's financial situation, including recurring losses and the need for additional funding, tempers the overall outlook. The going concern warning also adds a layer of concern.

Positives

• The ODYSSEY trial results for CLS-AX in wet AMD were positive, showing potential for reduced treatment burden.
• The company has a diversified pipeline of internal product candidates and external collaborations.
• The company has received regulatory certifications for its SCS Microinjector.
• The company has secured funding through a registered direct offering and a sales agreement.
• The company has a license agreement with BioCryst Pharmaceuticals, which includes an upfront payment and potential milestone payments.

Negatives

• The company has incurred significant net losses and negative cash flows since inception.
• The company has an accumulated deficit of $348.0 million as of September 30, 2024.
• The company's cash, cash equivalents, and short-term investments totaled $23.6 million as of September 30, 2024, which is a decrease from $28.9 million at the end of 2023.
• The company expects to continue to incur significant operating losses for the next several years.
• The company's financial statements have been prepared on a going concern basis, raising substantial doubt about its ability to continue as a going concern.
• The company is dependent on additional financing to fund future operations.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company is dependent on additional financing, which may not be available on favorable terms or at all.
• The company's product candidates may not receive regulatory approval or achieve commercial success.
• The company's financial results may fluctuate significantly from quarter to quarter and year to year.
• Macroeconomic conditions and global events may negatively affect the company's business and results of operations.
• The company's reliance on third parties for manufacturing and commercialization poses risks.

Future Outlook

The company expects its current cash, cash equivalents, and short-term investments to fund operations into the third quarter of 2025, but will require additional capital to complete the clinical development of CLS-AX and other product candidates. The company anticipates continuing to incur significant operating losses for the next several years and is exploring various financing options.

Management Comments

• Management believes that the company's proprietary suprachoroidal administration platform has the potential to become a standard for delivery of therapies intended to treat chorioretinal diseases.
• Management is leveraging the SCS injection platform by building an internal research and development pipeline targeting retinal diseases and by creating external collaborations with other companies.
• Management expects clinical trial expenses to increase in the remainder of 2024 as a result of the Phase 2b clinical trial of CLS-AX and activities related to preparation for a Phase 3 clinical trial of CLS-AX.

Industry Context

This announcement comes as the biopharmaceutical industry continues to focus on innovative drug delivery methods, particularly for ophthalmic treatments. The positive results from the ODYSSEY trial for CLS-AX could position Clearside as a key player in the wet AMD market, which is dominated by intravitreal injections. The company's focus on suprachoroidal delivery aligns with a growing trend towards targeted and less invasive therapies.

Comparison to Industry Standards

• The ODYSSEY trial results, showing a reduction in injection frequency, are notable compared to the standard of care for wet AMD, which typically requires monthly intravitreal injections of anti-VEGF agents like aflibercept (Eylea) and ranibizumab (Lucentis).
• Companies like Regeneron (Eylea) and Roche/Genentech (Lucentis, Vabysmo) are major players in the wet AMD market, and Clearside's CLS-AX, if successful in Phase 3 trials, could offer a competitive alternative with a potentially lower treatment burden.
• The development of suprachoroidal delivery is also being explored by other companies, such as REGENXBIO, which has a collaboration with Clearside, indicating a broader industry interest in this approach.
• The financial situation of Clearside, with its recurring losses and need for additional funding, is not uncommon for early-stage biopharmaceutical companies, many of which rely on venture capital and public offerings to fund their research and development.

Related Party Transactions

• A member of the company's Board of Directors is the chief executive officer of a company that is a vendor of the company, with $0.2 million in accounts payable and $0.3 million in accrued expense recorded as of September 30, 2024.
• The chair of the board of directors of BioCryst also serves on the company's Board of Directors, with $81,000 and $0.2 million recorded in license and other revenue for the three and nine months ended September 30, 2024, respectively, related to the BioCryst License Agreement.

Stakeholder Impact

• Shareholders face the risk of dilution from future equity offerings and potential loss of investment if the company is unable to continue as a going concern.
• Employees may be affected by potential cost-cutting measures or restructuring if the company's financial situation does not improve.
• Customers and partners may be impacted by delays or changes in the company's development and commercialization plans.
• Creditors face the risk of non-payment if the company is unable to secure additional financing.

Next Steps

• The company plans to conduct an End-of-Phase 2 meeting with the FDA in early 2025 to align on the essential components of its Phase 3 program for CLS-AX.
• The company is planning to run two Phase 3 trials with aflibercept 2 mg as a comparator for CLS-AX.
• The company will continue to evaluate small molecules for the potential treatment of geographic atrophy (GA).
• The company will continue to seek additional financing to fund its operations.

Key Dates

Keywords

suprachoroidal, SCS Microinjector, wet AMD, CLS-AX, XIPERE, clinical trial, biopharmaceutical, retinal diseases, macular edema, uveitis, license agreement, milestone payments, royalty, financial results, going concern